Lars Jørgen Østergaard

The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. / Hønge, Bo Langhoff; Jespersen, Sanne; Medina, Candida; Té, David da Silva; da Silva, Zacarias José; Christiansen, Mette; Kjerulff, Bertram; Laursen, Alex Lund; Wejse, Christian; Krarup, Henrik; Erikstrup, Christian; Bissau HIV cohort study group ; Østergaard, Lars Jørgen (Member of author collaboration).

In: HIV Medicine, Vol. 19, No. 6, 07.2018, p. 403-410.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Hønge, BL, Jespersen, S, Medina, C, Té, DDS, da Silva, ZJ, Christiansen, M, Kjerulff, B, Laursen, AL, Wejse, C, Krarup, H, Erikstrup, C, Bissau HIV cohort study group & Østergaard, LJ 2018, 'The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections', HIV Medicine, vol. 19, no. 6, pp. 403-410. https://doi.org/10.1111/hiv.12606

APA

CBE

MLA

Vancouver

Author

Hønge, Bo Langhoff ; Jespersen, Sanne ; Medina, Candida ; Té, David da Silva ; da Silva, Zacarias José ; Christiansen, Mette ; Kjerulff, Bertram ; Laursen, Alex Lund ; Wejse, Christian ; Krarup, Henrik ; Erikstrup, Christian ; Bissau HIV cohort study group ; Østergaard, Lars Jørgen. / The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. In: HIV Medicine. 2018 ; Vol. 19, No. 6. pp. 403-410.

Bibtex

@article{307df2e37d774704acc493f7b70f91fa,
title = "The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections",
abstract = "OBJECTIVES: Discrimination between HIV-1 and HIV-2 is important to ensure appropriate antiretroviral treatment (ART) and epidemiological surveillance. However, serological tests have shown frequent mistyping when applied in the field. We evaluated two confirmatory tests, INNO-LIA HIV I/II Score and ImmunoComb HIV 1/2 BiSpot, for HIV type discriminatory capacity.METHODS: Samples from 239 ART-na{\"i}ve HIV-infected patients from the Bissau HIV Cohort in Guinea-Bissau were selected retrospectively based on the initial HIV typing performed in Bissau, ensuring a broad representation of HIV types. INNO-LIA results were interpreted by the newest software algorithm, and three independent observers read the ImmunoComb results. HIV-1/HIV-2 RNA and DNA were measured for confirmation.RESULTS: INNO-LIA results showed 123 HIV-1 positive samples, 69 HIV-2 positive and 47 HIV-1/2 dually reactive. There was agreement between INNO-LIA and HIV-1/HIV-2 RNA and DNA detection, although not all HIV-1/2 dually reactive samples could be confirmed by the nucleic acid results. Overall, the observers found that the ImmunoComb results differed from the INNO-LIA results, with agreements of 90.4, 91.2 and 92.5%, respectively, for HIV-1, HIV-2 and HIV-1/2. The combined kappa-score for agreement between the three observers was 0.955 (z-score 35.1; P < 0.01). Of the HIV-2 mono-reactive samples (INNO-LIA), the three observers interpreted 24.6-31.9% as HIV-1/2 dually infected by ImmunoComb. None of these samples had detectable HIV-1 RNA or DNA.CONCLUSIONS: There was accordance between INNO-LIA calls and nucleic acid results, whereas ImmunoComb overestimated the number of HIV-1/2 dually infected patients. Confirmatory typing is needed for patients diagnosed with HIV-1/2 dual infection by ImmunoComb.",
author = "H{\o}nge, {Bo Langhoff} and Sanne Jespersen and Candida Medina and T{\'e}, {David da Silva} and {da Silva}, {Zacarias Jos{\'e}} and Mette Christiansen and Bertram Kjerulff and Laursen, {Alex Lund} and Christian Wejse and Henrik Krarup and Christian Erikstrup and {Bissau HIV cohort study group} and {\O}stergaard, {Lars J{\o}rgen}",
note = "{\textcopyright} 2018 British HIV Association.",
year = "2018",
month = jul,
doi = "10.1111/hiv.12606",
language = "English",
volume = "19",
pages = "403--410",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections

AU - Hønge, Bo Langhoff

AU - Jespersen, Sanne

AU - Medina, Candida

AU - Té, David da Silva

AU - da Silva, Zacarias José

AU - Christiansen, Mette

AU - Kjerulff, Bertram

AU - Laursen, Alex Lund

AU - Wejse, Christian

AU - Krarup, Henrik

AU - Erikstrup, Christian

AU - Bissau HIV cohort study group

AU - Østergaard, Lars Jørgen

N1 - © 2018 British HIV Association.

PY - 2018/7

Y1 - 2018/7

N2 - OBJECTIVES: Discrimination between HIV-1 and HIV-2 is important to ensure appropriate antiretroviral treatment (ART) and epidemiological surveillance. However, serological tests have shown frequent mistyping when applied in the field. We evaluated two confirmatory tests, INNO-LIA HIV I/II Score and ImmunoComb HIV 1/2 BiSpot, for HIV type discriminatory capacity.METHODS: Samples from 239 ART-naïve HIV-infected patients from the Bissau HIV Cohort in Guinea-Bissau were selected retrospectively based on the initial HIV typing performed in Bissau, ensuring a broad representation of HIV types. INNO-LIA results were interpreted by the newest software algorithm, and three independent observers read the ImmunoComb results. HIV-1/HIV-2 RNA and DNA were measured for confirmation.RESULTS: INNO-LIA results showed 123 HIV-1 positive samples, 69 HIV-2 positive and 47 HIV-1/2 dually reactive. There was agreement between INNO-LIA and HIV-1/HIV-2 RNA and DNA detection, although not all HIV-1/2 dually reactive samples could be confirmed by the nucleic acid results. Overall, the observers found that the ImmunoComb results differed from the INNO-LIA results, with agreements of 90.4, 91.2 and 92.5%, respectively, for HIV-1, HIV-2 and HIV-1/2. The combined kappa-score for agreement between the three observers was 0.955 (z-score 35.1; P < 0.01). Of the HIV-2 mono-reactive samples (INNO-LIA), the three observers interpreted 24.6-31.9% as HIV-1/2 dually infected by ImmunoComb. None of these samples had detectable HIV-1 RNA or DNA.CONCLUSIONS: There was accordance between INNO-LIA calls and nucleic acid results, whereas ImmunoComb overestimated the number of HIV-1/2 dually infected patients. Confirmatory typing is needed for patients diagnosed with HIV-1/2 dual infection by ImmunoComb.

AB - OBJECTIVES: Discrimination between HIV-1 and HIV-2 is important to ensure appropriate antiretroviral treatment (ART) and epidemiological surveillance. However, serological tests have shown frequent mistyping when applied in the field. We evaluated two confirmatory tests, INNO-LIA HIV I/II Score and ImmunoComb HIV 1/2 BiSpot, for HIV type discriminatory capacity.METHODS: Samples from 239 ART-naïve HIV-infected patients from the Bissau HIV Cohort in Guinea-Bissau were selected retrospectively based on the initial HIV typing performed in Bissau, ensuring a broad representation of HIV types. INNO-LIA results were interpreted by the newest software algorithm, and three independent observers read the ImmunoComb results. HIV-1/HIV-2 RNA and DNA were measured for confirmation.RESULTS: INNO-LIA results showed 123 HIV-1 positive samples, 69 HIV-2 positive and 47 HIV-1/2 dually reactive. There was agreement between INNO-LIA and HIV-1/HIV-2 RNA and DNA detection, although not all HIV-1/2 dually reactive samples could be confirmed by the nucleic acid results. Overall, the observers found that the ImmunoComb results differed from the INNO-LIA results, with agreements of 90.4, 91.2 and 92.5%, respectively, for HIV-1, HIV-2 and HIV-1/2. The combined kappa-score for agreement between the three observers was 0.955 (z-score 35.1; P < 0.01). Of the HIV-2 mono-reactive samples (INNO-LIA), the three observers interpreted 24.6-31.9% as HIV-1/2 dually infected by ImmunoComb. None of these samples had detectable HIV-1 RNA or DNA.CONCLUSIONS: There was accordance between INNO-LIA calls and nucleic acid results, whereas ImmunoComb overestimated the number of HIV-1/2 dually infected patients. Confirmatory typing is needed for patients diagnosed with HIV-1/2 dual infection by ImmunoComb.

U2 - 10.1111/hiv.12606

DO - 10.1111/hiv.12606

M3 - Journal article

C2 - 29573304

VL - 19

SP - 403

EP - 410

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 6

ER -